{"url_path":"/sec/ctxr/8-k/2026-05-08/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-053916-index.html","accession_number":"0001213900-26-053916","cik":"0001506251","ticker":"CTXR","issuer_name":"Citius Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506251/0001213900-26-053916-index.html","primary_entity_key":"0001506251","primary_entity_name":"Citius Pharmaceuticals, Inc."},"word_count":102,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) The following exhibits are being\nfiled with this Current Report on Form 8-K.\n\n \n\n**Exhibit**\n \n**Description**\n\n10.1\n \n[Third Amendment to Promissory Note, dated as of May 4, 2026, between the Company and Citius Oncology.](ea028973101ex10-1.htm)\n\n104\n \nCover Page Interactive Date File (embedded within the Inline XBRL document).\n\n \n\n1\n\n \n\nSIGNATURE\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**CITIUS PHARMACEUTICALS, INC.**\n\n \n \n\nDate: May 8, 2026\n/s/ Leonard Mazur\n\n \nLeonard Mazur\n\n \nChairman and Chief Executive Officer\n\n \n\n2"}